Australia markets close in 4 hours 14 minutes
  • ALL ORDS

    7,754.40
    +25.90 (+0.34%)
     
  • ASX 200

    7,539.70
    +28.10 (+0.37%)
     
  • AUD/USD

    0.7071
    -0.0011 (-0.15%)
     
  • OIL

    76.04
    +0.16 (+0.21%)
     
  • GOLD

    1,930.10
    -0.70 (-0.04%)
     
  • BTC-AUD

    33,333.95
    -1,041.34 (-3.03%)
     
  • CMC Crypto 200

    537.27
    -8.05 (-1.48%)
     
  • AUD/EUR

    0.6486
    +0.0001 (+0.02%)
     
  • AUD/NZD

    1.0922
    -0.0007 (-0.07%)
     
  • NZX 50

    12,161.86
    +9.70 (+0.08%)
     
  • NASDAQ

    12,803.14
    +440.04 (+3.56%)
     
  • FTSE

    7,820.16
    +59.05 (+0.76%)
     
  • Dow Jones

    34,053.94
    -39.02 (-0.11%)
     
  • DAX

    15,509.19
    +328.45 (+2.16%)
     
  • Hang Seng

    21,958.36
    -113.82 (-0.52%)
     
  • NIKKEI 225

    27,555.75
    +153.70 (+0.56%)
     

Bristol Myers Squibb Announces Dividend Increase

NEW YORK, December 08, 2022--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2023 to stockholders of record at the close of business on January 6, 2023.

This quarterly dividend represents a 5.6% increase over last year’s quarterly dividend rate of fifty-four cents ($0.54) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2023 is $2.28 per share. This marks the fourteenth consecutive fiscal year that the company has increased its dividend and the 91st consecutive year that the company has paid a dividend.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 1, 2023 to stockholders of record at the close of business on January 31, 2023.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208006029/en/

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com